Success Metrics

Clinical Success Rate

100.0%

Based on 2 completed trials

Completion Rate

100%(2/2)

Active Trials

3(38%)

Results Posted

0%(0 trials)

Phase Distribution

Ph not_applicable

13%

Ph phase_3

25%

Ph phase_2

38%

Ph early_phase_1

13%

Ph phase_4

13%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution8 total trials

Early Phase 1First-in-human

1(12.5%)

Phase 2Efficacy & side effects

3(37.5%)

Phase 3Large-scale testing

2(25.0%)

Phase 4Post-market surveillance

1(12.5%)

N/ANon-phased studies

1(12.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(5)

Completed(2)

Other(1)

Detailed Status

Recruiting3

Completed2

Enrolling by invitation1

Not yet recruiting1

unknown1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 4

Trials by Phase

Early Phase 11 (12.5%)

Phase 23 (37.5%)

Phase 32 (25.0%)

Phase 41 (12.5%)

N/A1 (12.5%)

Trials by Status

recruiting338%

enrolling_by_invitation113%

completed225%

not_yet_recruiting113%

unknown113%

Recent Activity

3 active trials

Showing 5 of 8

completedearly_phase_1

A Pilot Study of Fenofibrate and Ursodeoxycholic Acid in the Treatment of Newly Diagnosed Primary Biliary Cholangitis

NCT06591455

recruitingphase_2

Perioperative Ursodeoxycholic Acid for Renal Protection in Adults Undergoing Partial Nephrectomy for Renal Tumors

NCT07672860

not_yet_recruitingphase_2

Comparing UDCA and Corticosteroids in Immunotherapy Induced Cholestatic Hepatitis

NCT07378761

recruitingphase_3

FIREFLY Trial: Fenofibrate Intervention---Randomized Evaluation in First-Line PBC Therapy

NCT07296458

enrolling_by_invitationphase_2

A Multicenter, Randomized, Controlled Trial of Prednisone Combined With Ursodeoxycholic Acid in the Treatment of Primary Biliary Cholangitis With Moderate to Severe Interface Hepatitis Characteristics

NCT06591468

View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials

NCT06591455Early Phase 1

A Pilot Study of Fenofibrate and Ursodeoxycholic Acid in the Treatment of Newly Diagnosed Primary Biliary Cholangitis

Completed

NCT07672860Phase 2

Perioperative Ursodeoxycholic Acid for Renal Protection in Adults Undergoing Partial Nephrectomy for Renal Tumors

Recruiting

NCT07378761Phase 2

Comparing UDCA and Corticosteroids in Immunotherapy Induced Cholestatic Hepatitis

Not Yet Recruiting

NCT07296458Phase 3

FIREFLY Trial: Fenofibrate Intervention---Randomized Evaluation in First-Line PBC Therapy

Recruiting

NCT06591468Phase 2

A Multicenter, Randomized, Controlled Trial of Prednisone Combined With Ursodeoxycholic Acid in the Treatment of Primary Biliary Cholangitis With Moderate to Severe Interface Hepatitis Characteristics

Enrolling By Invitation

NCT07068191Not Applicable

Gepaktiv vs UDCA and Ademetionine in MAFLD With Hepatomegaly

Recruiting

NCT05416580Phase 3

Efficacy of Ursodeoxycholic Acid (UDCA) in Patients With Type 2 Diabetes

Unknown

NCT01510860Phase 4

Ursofalk Tablets (500 mg) Versus Ursofalk Capsules (250 mg) in the Treatment of Primary Biliary Cirrhosis

Completed

All 8 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 8